Eosinophilic Esophagitis

Compared with adult patients who more frequently experienced delayed eosinophilic esophagitis diagnosis, pediatric patients had higher endoscopic findings of the disease with increased eosinophils detected during esophageal biopsy.

During induction, budesonide tablets were effective in increasing esophageal distensibility in eosinophilic esophagitis and was further improved during maintenance therapy, according to a presenter at UEG Week.

Compared with placebo, dupilumab was safe and improved eosinophilic esophagitis at 24 and 52 weeks, according to a presentation at UEG Week Virtual.

Approximately 1% of patients on peanut allergen powder oral immunotherapy developed eosinophilic esophagitis, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Unsedated transnasal esophagoscopy with virtual reality distraction may more quickly establish eosinophilic esophagitis treatment, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Healio Gastroenterology presents the following report on the top peer-tested stories in April.

In patients with eosinophilic esophagitis, budesonide oral suspension improved histologic, symptomatic and endoscopic outcomes, according to research published in Clinical Gastroenterology and Hepatology.

More than half of pediatric patients with eosinophilic esophagitis experienced histologic remission after going on a milk elimination diet, according to study results.

In this video exclusive, Mena Boules, MD, medical director of Takeda Pharmaceuticals, discussed the program See EoE, which was designed to raise awareness of eosinophilic esophagitis among physicians.

Twice-daily budesonide oral suspension, or BOS, improved outcomes in pediatric patients with eosinophilic esophagitis, according to research presented at this year’s virtual American Academy of Allergy, Asthma and Immunology Annual Meeting.